[go: up one dir, main page]

WO2009001222A3 - METHOD FOR SCREENING FOR SELECTIVE MODULATOR OF THE NF-ϰB PATHWAY ACTIVATION - Google Patents

METHOD FOR SCREENING FOR SELECTIVE MODULATOR OF THE NF-ϰB PATHWAY ACTIVATION Download PDF

Info

Publication number
WO2009001222A3
WO2009001222A3 PCT/IB2008/002633 IB2008002633W WO2009001222A3 WO 2009001222 A3 WO2009001222 A3 WO 2009001222A3 IB 2008002633 W IB2008002633 W IB 2008002633W WO 2009001222 A3 WO2009001222 A3 WO 2009001222A3
Authority
WO
WIPO (PCT)
Prior art keywords
kappav
screening
pathway activation
selective modulator
modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/002633
Other languages
French (fr)
Other versions
WO2009001222A2 (en
Inventor
Fabrice Agou
Jeanne Chiaravalli
Yves-Marie Coic
Francoise Baleux
Alain Israel
Michel Veron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08807211A priority Critical patent/EP2174141A2/en
Priority to BRPI0814721-3A2A priority patent/BRPI0814721A2/en
Priority to JP2010512810A priority patent/JP2010530970A/en
Priority to AU2008269444A priority patent/AU2008269444A1/en
Priority to CA002692112A priority patent/CA2692112A1/en
Priority to CN200880104245A priority patent/CN101802619A/en
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur filed Critical Centre National de la Recherche Scientifique CNRS
Priority to US12/666,128 priority patent/US20100240040A1/en
Publication of WO2009001222A2 publication Critical patent/WO2009001222A2/en
Publication of WO2009001222A3 publication Critical patent/WO2009001222A3/en
Priority to IL202760A priority patent/IL202760A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to methods for screening for selective modulator of NF-ϰB pathway activation. The invention concerns methods for primary screening molecules that potentially modulate (activate or inhibit) the NF-ϰB pathway activation by identifying and selecting molecules modulate the interaction of NEMO with other proteins. The invention also concerns methods for secondary screening for modulator (activator or inhibitor) of the NF-ϰB pathway activation.
PCT/IB2008/002633 2007-06-22 2008-06-20 METHOD FOR SCREENING FOR SELECTIVE MODULATOR OF THE NF-ϰB PATHWAY ACTIVATION Ceased WO2009001222A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0814721-3A2A BRPI0814721A2 (en) 2007-06-22 2008-06-20 NF-kB ACTIVATION SELECTIVE MODULATOR CLASSIFICATION METHOD
JP2010512810A JP2010530970A (en) 2007-06-22 2008-06-20 Method for screening selective modulator of NF-κB pathway activation
AU2008269444A AU2008269444A1 (en) 2007-06-22 2008-06-20 Method for screening for selective modulator of the NF-kB pathway activation
CA002692112A CA2692112A1 (en) 2007-06-22 2008-06-20 Method for screening for selective modulator of the nf-kb pathway activation
CN200880104245A CN101802619A (en) 2007-06-22 2008-06-20 Method of screening for selective modulators of NF-κB pathway activation
EP08807211A EP2174141A2 (en) 2007-06-22 2008-06-20 Method for screening for selective modulator of the nf- b pathway activation
US12/666,128 US20100240040A1 (en) 2007-06-22 2008-06-20 Method for screening for selective modulator of the nf-kb pathway activation
IL202760A IL202760A0 (en) 2007-06-22 2009-12-15 METHOD FOR SCREENING FORSELECTIVE MODULATOR OF THE NF-kB PATHWAY ACTIVATION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290782A EP2006686A1 (en) 2007-06-22 2007-06-22 Method for screening for selective modulator of the NF-kB pathway activation
EP07290782.7 2007-06-22

Publications (2)

Publication Number Publication Date
WO2009001222A2 WO2009001222A2 (en) 2008-12-31
WO2009001222A3 true WO2009001222A3 (en) 2009-05-22

Family

ID=38577422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002633 Ceased WO2009001222A2 (en) 2007-06-22 2008-06-20 METHOD FOR SCREENING FOR SELECTIVE MODULATOR OF THE NF-ϰB PATHWAY ACTIVATION

Country Status (9)

Country Link
US (1) US20100240040A1 (en)
EP (2) EP2006686A1 (en)
JP (1) JP2010530970A (en)
CN (1) CN101802619A (en)
AU (1) AU2008269444A1 (en)
BR (1) BRPI0814721A2 (en)
CA (1) CA2692112A1 (en)
IL (1) IL202760A0 (en)
WO (1) WO2009001222A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104871001B (en) * 2012-12-12 2018-09-11 普洛麦格公司 Identification of cellular target binding of bioactive agents using intracellular bioluminescence resonance energy transfer
CN107271687A (en) * 2017-07-14 2017-10-20 郑州大学 Utilize the method for HTRF technology screening UBC12/Dcn1 micromolecular inhibitors
US20210355221A1 (en) * 2018-10-18 2021-11-18 The General Hospital Corporation Targeting the Non-Canonical NFkB Pathway in Cancer Immunotherapy
EP4229211A4 (en) * 2020-10-15 2025-04-02 SRI International BINDING ASSAYS INVOLVING A PLURALITY OF SYNTHETIC COMPOUNDS, TARGETS, AND COUNTERTARGETS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020458A2 (en) * 2002-08-30 2004-03-11 Rigel Pharmaceuticals, Inc. Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents
WO2005027959A1 (en) * 2003-09-24 2005-03-31 Institut Pasteur Selective inhibition of nf-kappab activation by peptides designed to disrupt nemo oligomerization.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020458A2 (en) * 2002-08-30 2004-03-11 Rigel Pharmaceuticals, Inc. Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents
WO2005027959A1 (en) * 2003-09-24 2005-03-31 Institut Pasteur Selective inhibition of nf-kappab activation by peptides designed to disrupt nemo oligomerization.

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AGOU F ET AL: "Inhibition of NF-kB activation by peptides targeting NF-kB essential modulator (NEMO) oligomerization", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 279, no. 52, 24 December 2004 (2004-12-24), pages 54248 - 54257, XP002314352, ISSN: 0021-9258 *
GOHDA JIN ET AL: "HTLV-1 Tax-induced NFkappaB activation is independent of Lys-63-linked-type polyubiquitination.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 25 MAY 2007, vol. 357, no. 1, 25 May 2007 (2007-05-25), pages 225 - 230, XP022022995, ISSN: 0006-291X *
WYLER EMANUEL ET AL: "Inhibition of NF-kappaB activation with designed ankyrin-repeat proteins targeting the ubiquitin-binding/oligomerization domain of NEMO.", PROTEIN SCIENCE : A PUBLICATION OF THE PROTEIN SOCIETY SEP 2007, vol. 16, no. 9, September 2007 (2007-09-01), pages 2013 - 2022, XP008085017, ISSN: 0961-8368 *
ZHOU H ET AL: "Bcl10 activates the NF-[kappa]B pathway through ubiquitination of NEMO", NATURE 08 JAN 2004 UNITED KINGDOM, vol. 427, no. 6970, 8 January 2004 (2004-01-08), pages 167 - 171, XP002468483, ISSN: 0028-0836 *
ZHU ET AL: "Optineurin Negatively Regulates TNFalpha- Induced NF-kappaB Activation by Competing with NEMO for Ubiquitinated RIP", CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 17, no. 16, 21 August 2007 (2007-08-21), pages 1438 - 1443, XP022206193, ISSN: 0960-9822 *

Also Published As

Publication number Publication date
CN101802619A (en) 2010-08-11
BRPI0814721A2 (en) 2015-02-24
IL202760A0 (en) 2010-06-30
EP2006686A1 (en) 2008-12-24
CA2692112A1 (en) 2008-12-31
US20100240040A1 (en) 2010-09-23
EP2174141A2 (en) 2010-04-14
JP2010530970A (en) 2010-09-16
AU2008269444A1 (en) 2008-12-31
WO2009001222A2 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
WO2009064920A3 (en) Compounds and methods for modulating protein expression
WO2008002676A3 (en) Biaryl compositions and methods for modulating a kinase cascade
WO2005118857A3 (en) Methods and agents for screening for compounds capable of modulating vegf expression
WO2011038301A3 (en) Screening methods
WO2007084321A3 (en) Antibodies to ox-2/cd200 and uses thereof
ATE513833T1 (en) THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
WO2010087994A3 (en) Methods for ligation and uses thereof
WO2008002674A3 (en) Bicyclic compositions and methods for modulating a kinase cascade
ATE504836T1 (en) METHOD FOR IDENTIFYING TRPV2 MODULATORS
MX2009004167A (en) Antibodies that bind cxcr7 epitopes.
WO2009009041A3 (en) Compositions and methods for modulating a kinase cascade
WO2008091681A3 (en) Theramutein modulators
WO2007094755A3 (en) Compositions and methods for modulating cognitive function
WO2005028678A3 (en) Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
WO2008118626A3 (en) Inhibitors of jnk and methods for identifying inhibitors of jnk
WO2010138814A3 (en) Disrupting fcrn-albumin interactions
WO2008020942A3 (en) R-spondin compositions and methods of use thereof
WO2007120766A3 (en) Erythropoietin receptor agonists
WO2007025247A3 (en) Transglutaminase inhibitors and methods of use thereof
WO2008085900A3 (en) Methods for generating novel stabilized proteins
WO2008066869A3 (en) Systems and methods for monitoring the amplification and dissociation behavior of dna molecules
WO2007076174A3 (en) Methods, systems, and apparatus for multi-domain markers
WO2009001222A3 (en) METHOD FOR SCREENING FOR SELECTIVE MODULATOR OF THE NF-ϰB PATHWAY ACTIVATION
WO2007050795A3 (en) Transglutaminase inhibitors and methods of use thereof
WO2006042173A3 (en) Modulators of hepatocyte growth factor activator

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880104245.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08807211

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2692112

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010512810

Country of ref document: JP

Ref document number: 2008269444

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 8406/DELNP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008269444

Country of ref document: AU

Date of ref document: 20080620

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008807211

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12666128

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0814721

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091222